MUCOLASE 5% SYRUP 120ML

ABSTRACT PRESCRIPTION OF MUCOACTIVE DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS INCREASING. THIS DEVELOPMENT IN CLINICAL PRACTICE ARISES AT LEAST IN PART FROM A GROWING UNDERSTANDING OF THE IMPORTANT ROLE THAT EXACERBATION FREQUENCY SYSTEMIC INFLAMMATION AND OXIDATIVE STRESS PLAY IN THE PATHOGENESIS OF RESPIRATORY DISEASE. S-CARBOXYMETHYLCYSTEINE (CARBOCISTEINE) IS THE MOST FREQUENTLY PRESCRIBED MUCOACTIVE AGENT FOR LONG-TERM COPD USE IN THE UK. IN ADDITION TO ITS MUCOREGULATORY ACTIVITY CARBOCISTEINE EXHIBITS FREE-RADICAL SCAVENGING AND ANTI-INFLAMMATORY PROPERTIES. THESE CHARACTERISTICS HAVE STIMULATED INTEREST IN THE POTENTIAL THAT THIS AND OTHER MUCOACTIVE DRUGS MAY OFFER FOR MODIFICATION OF THE DISEASE PROCESSES PRESENT IN COPD.